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Background
Altered response to acute catecholamine increase in the synaptic
cleft is considered to be the mechanism underlying transient
left ventricular apical ballooning syndrome (LVABS).1 –3 Cardiac
adrenergic receptors (ARs) of the b1 and b2 subtypes4 activate
myocytes by coupling to the Ga subunit of the heterotrimeric
Gs protein, but on the other hand they also promote G protein
coupled receptor kinase (GRK)-mediated phosphorylation of
bAR with the intent to shut-off signalling.5 The impact on
cardiac function of genetic variants of molecules involved in the
intracellular pathways of bAR signalling has been extensively
investigated.6 –8
Aims
We postulated that polymorphisms associated with different bAR
responsiveness might play a role in the risk of LVABS, thus allowing
the identification of those patients that are prone to LVABS after
an adrenergic surge.
Methods
We prospectively enrolled 22 consecutive LVABS patients (4 men, age
63+13 years) admitted to the Intensive Coronary Care unit of the
AOP Federico II, Naples, Italy between 2005 and 2008. Peripheral
blood samples were collected from each patient for genetic analysis.
The results were compared with those of 740 outpatients (control)
aged 50+0.4 years, 57.8% male. To replicate the study in an indepen-
dent population, we also enrolled 376 normal volunteers who had
undergone voluntary screening for cardiovascular disease, hyperten-
sion, diabetes, and kidney failure at our outpatient clinic. The study
was approved by the Federico II Ethical Committee and all subjects
gave written informed consent. Each LVABS patient underwent
standard echocardiography at admission, serially before discharge,
and at an outpatient visit performed 3–4 weeks after the onset of
symptoms. A 16-segment model and a score from 1 (normal) to 4
(dyskinesia) were used for wall motion analysis. Left ventricular ejec-
tion fraction was measured using the biplane Simpson’s rule.
The following polymorphisms were analysed: rs35230616 and
rs1801253 for b1AR; rs1042713, rs1042714, and rs1800888 for
b2AR; rs11554276 for Gs-protein alpha subunit (GNAS);
rs17098707 and rs34679178 for GRK5. Genomic DNA was
extracted from white blood cells using a dedicated workstation
(MagRo; BioNobile) and polymerase chain reaction followed by
restriction fragment length polymorphism analysis.
Data are expressed as mean+ standard deviation or as a percen-
tage; x2 test, the Cochran–Mantel–Haenszel analysis, and one-way
analysis of variance (ANOVA) with a Bonferroni post hoc test were
used as appropriate (SPSS 13.0). A value of P, 0.05 was considered
statistically significant.
Results
The demographic and clinical characteristics of the LVABS patients
are shown in Table 1. Two patients had bronchial asthma and
were receiving chronic treatment with long-acting beta stimulating
agents. In one patient, LVABS occurred after the intravenous admin-
istration of epinephrine during an asthma attack. A stressful event
was identified as the precipitating factor in each of the remaining
cases (physical, n ¼ 1 and emotional, n ¼ 20). The results of the
genetic analysis are reported in Table 2. The prevalence of poly-
morphisms of b1AR, b2AR, and GNAS were similar between
patients and controls. Conversely, the percentage of LVABS patients
who presented with the rs17098707 polymorphism of the GRK5
gene was significantly higher. This genetic variant causes a leucine
(L) substitution of the glutamine (Q) amino acid at position 41.
The OR for GRK5 for the L41 variant to cause LVABS was 4.036
with a confidence interval of 1.443–11.286 (P, 0.01).
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The frequency of the GRK5 L41 allele in the replication cohort
was similar to that observed in the control population (Q/Q:
57.4%; L/Q: 37.2%; L/L: 5.3%, n.s.). The clinical characteristics of
this group are depicted in Table 3. Interestingly, a significantly
lower heart rate was associated with the presence of one or
two L41 alleles of GRK5. This difference held true in the female
group (b.p.m.; Q/Q: 75.6+1.4, L/Q: 73.2+1.2, L/L: 67.8+ 3.0;
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Table 1 Demographic, clinical, and echocardiographic characteristics of left ventricular apical ballooning syndrome
patients




1 40 m þ þ 2 2 1.94 40
2 58 f þ þ 2 þ 1.7 42
3 74 f þ þ þ 2 2.125 33
4 52 m þ 2 2 2 2.125 39
5 45 f 2 2 2 2 1.4 45
6 62 m þ 2 2 þ 2.3 35
7 54 f þ 2 2 2 2.4 31
8 66 f þ þ þ þ 2.15 36
9 78 f þ þ 2 2 2.7 38
10 55 f þ þ 2 þ 2.5 33
11 77 f þ þ 2 þ 2.25 39
12 80 m þ 2 2 2 2.1 32
13 46 f 2 þ 2 2 2.,3 40
14 84 f þ þ 2 2 2. 5 30
15 84 f þ 2 þ 2 1.84 40
16 64 f þ þ þ 2 1.9 41
17 56 f 2 þ 2 2 2.3 33
18 50 f 2 2 2 þ 2.1 38
19 66 f þ þ 2 2 2.5 32
20 59 f 2 2 2 þ 2.25 36
21 51 f 2 þ 2 2 2.3 35
22 66 f þ þ þ 2 2.1 37
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Table 2 Frequencies of the studied polymorphisms in the left ventricular apical ballooning syndrome and in the control
populations
Gene (SNP) Group WT (%) Het (%) Poly (%) Pearson x2 P-value
b1AR Q31R (rs35230616) Control 83.2 15.0 1.7 0.42 n.s.
LVABS 81.3 18.8 0.0
b1AR G389R (rs1801253) Control 68.6 31.4 0.0 8.03 n.s.
LVABS 63.6 31.8 4.5
b2AR G16R (rs1042713) Control 53 45 12 3.80 n.s.
LVABS 58 38 4
b2AR E27Q (rs1042714) Control 59.4 33.2 7.4 2.81 n.s.
LVABS 45.8 50.0 4.2
b2AR T164I (rs1800888) Control 96.8 3.2 — 0.69 n.s.
LVABS 100.0 0.0 —
Gas S51F (rs11554276) Control 44.6 47.4 8.0 2.82 n.s.
LVABS 60.0 40.0 0.0
GRK5 Q41L (rs17098707) Control 56.3 37.9 5.8 9.70 0.01
LVABS 36.0 44.0 20.0
GRK5 T129M (rs34679178) Control 83.1 16.9 — 3.46 n.s.
LVABS 100.0 0.0 —
Statistically significant results are highlighted in bold.























F ¼ 4.034, P, 0.02), whereas in the male group, due to the small
number of cases, significance held true only when the subjects
were dichotomized in bearer to not bearer of the mutated allele
(P, 0.05).
Conclusion
We did not find any difference in the frequency of b1AR, b2AR,
and GNAS S51F polymorphisms between LVABS patients and con-
trols. Conversely, LVABS patients exhibited a higher prevalence of
the leucine (L) over the glutamine (N) variant at amino acid 41 of
GRK5 non-catalytic regulatory domain. In the replication study,
heart rate was reduced in subjects bearing the L41 variant of the
GRK5. These findings are consistent with the notion that L41
GRK5 enhances receptor desensitization and impairs bAR
response.6 We envision two scenarios for the pathogenesis of
transient LVABS. First of all, the polymorphism might attenuate
the inotropic effect of catecholamines on cardiomyocytes.
Indeed, both in isolated cells and in transgenic mice, it has been
demonstrated that the GRK5 L41 variant causes a negative inotro-
pic effect under conditions of acute catecholamine stimulation.6
The greater bAR density at the apex when compared with the
basal myocardium would account for the characteristic distribution
of the wall motion abnormalities in the most common presen-
tation.9 Concurrently, an impairment in coronary blood flow
might contribute to myocardial stunning.10,11 Increased mechanical
wall stress as a consequence of apical ballooning may per se induce
coronary microcirculatory abnormalities and GRK5 41L
polymorphism, which enhances bAR desensitization, might
induce an imbalance between a1 coronary vasoconstriction and
bAR vasodilation.12 This is the first study demonstrating a link
between a polymorphism of one of the protein kinases most
expressed in the heart and stress-induced acute ventricular
dysfunction. The possibility of recurrence and case reports
evaluating LVABS in relatives, support a genetic approach to the
pathophysiology of this syndrome.13
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